** Drug developer Amylyx Pharmaceuticals' AMLX.O shares fall 3.5% to $2.89
** Company posts Q4 net loss of $37.5 million compared with net income of $4.7 million a year ago
** AMLX closes its underwritten public offering of 19.7 million shares with net proceeds of about $65.5 million
** The offering extends the company's cash runway through the end of 2026
** In the last 12 months, AMLX has fallen 84%
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。